The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Canna Law Blog

OCTOBER 17, 2022

John presented incredibly interesting points and data, including the fact that most congressional candidates running in these mid-term elections hardly even mentioned the word marijuana when stumping. Missouri has collected less than $10 million since sales began. let alone talked about legalizing it. What does that mean?

Legalization 91

Legalization Banking Research and Development Policy 91

The Blunt Truth

AUGUST 13, 2019

On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. The FDA is collecting data to fill these gaps. The public hearing attracted over 100 speakers and 2000 participants. What’s Next?

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

MARCH 19, 2020

2 At the conclusion of the meeting, FDA stated that it would form an internal working group to study data gaps relating to CBD. As indicated by FDA’s recent announcement, the collection of data about the risks and benefits of CBD remains a priority for the agency.

CBD 45

CBD Research and Development Seed-To-Sale Data 45

Cannabis Law Report

AUGUST 3, 2021

In addition to FDM and e-commerce, the Transaction provides added distribution channels, increasing HempFusion’s 5 channel strategy to 6 channels and bolstering topical product distribution sales. Robust eCommerce platform drives over 17,000 average monthly sessions, and nearly $2.0 Chief Executive Officer of HempFusion. “We

Research and Development 105

Research and Development Topical Events Compliance 105

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Puff Puff Post

NOVEMBER 5, 2019

INM-755 is a single-cannabinoid topical cream under development for the treatment of symptoms associated with epidermolysis bullosa (“EB”). INM-755 cream is a proprietary, topical, single-cannabinoid product candidate intended as a therapy in epidermolysis bullosa (EB) and potentially other dermatological applications.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

JANUARY 12, 2022

In accordance with FDA requirements, an independent panel of qualified experts reviewed HempFusion’s safety dossier on its hemp-derived CBD extract, which included safety and toxicology studies, the published results of these studies, and a comprehensive review of the scientific literature on CBD. HempFusion Wellness Inc.

Retail 52

Retail CBD Extraction Research and Development 52

Cannabis Law Report

AUGUST 27, 2021

Built on a foundation of regulatory compliance and human safety, HempFusion Wellness offers a diverse product portfolio comprising of over 75 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. HempFusion Wellness Inc. FORWARD-LOOKING STATEMENTS.

Research and Development 105

Research and Development Events Hemp Food 105

Cannabis Law Report

MAY 6, 2022

The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. In short, the FDA has not evaluated or logged all dangerous side effects or safety concerns. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”. Taking CBD can relieve pain.”. “In

THC 52

THC CBD Media Food 52

Cannabis Law Report

FEBRUARY 19, 2020

3, 2020)—was brought by two plaintiffs who purchased products that contain hemp-derived cannabidiol (CBD), including edibles (gummies, syrups, tea, and coffee); supplements (capsules); and cosmetics (topicals), from defendant Green Roads, the products’ manufacturer and retailer.

CBD 45

CBD Retail Extraction Hemp 45

Cannabis Law Report

AUGUST 25, 2021

The #1 brand in CBD topicals, with 23% market share in the Drug channel [Drug (IRI-SPINScan 52 week ending 7-11-2021)] and 13.8-per-cent pull week ending 5/22/21)]. With a strong focus on research and development, HempFusion has an additional 30 products under development. FORWARD-LOOKING STATEMENTS.

Retail 111

Retail Supply Chain Research and Development Events 111

CannaMD

SEPTEMBER 10, 2020

This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented. But despite these revelations, both messaging and legalities have lagged.

Marijuana 59

Marijuana Therapy Data THC 59

Cannabis Law Report

JANUARY 23, 2020

As such, the Bureau finds that immediate action to amend the Bureau’s regulations is required to avoid serious harm to the public peace, health, safety, and general welfare. From these cases, the CDC collected fluid samples from the lungs of 29 patients. & Prof. Code, §26000, et seq.)

Vaping 64

Vaping THC Retail Safety 64

Marijuana Packaging

OCTOBER 25, 2018

If all of the proper warning labels are in place, inhalable, single-serving, and topical items will still be able to rely on one-time use child-resistant marijuana containers. At this point, multi-use products will be required to feature resealable child-resistant packaging unless the doses are individually packaged for child-resistance.

Cannabinoids 40

Cannabinoids Packaging Recreational Cannabis 40

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Data collection.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

AUGUST 16, 2021

Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. FORWARD-LOOKING STATEMENTS.

eCommerce 105

eCommerce Retail Research and Development CBD 105

Otherside Farms

DECEMBER 10, 2019

While there are no comprehensive scientific data on victimization CBD to treat dogs, there’s anecdotal proof from doghouse owners suggesting it will treat pain, particularly neuropathic pain, moreover, as serving to manage seizures. The safety and risks of CBD for dogs haven’t but been researched. Risks of CBD Oil for Dogs.

Oil 18

Oil CBD Pets Blood Pressure 18

Cannabis Law Report

NOVEMBER 2, 2021

We wanted to investigate, so after collecting samples from online stores and brick-and-mortar smoke shops, we commissioned FESA Labs to perform independent testing on 51 delta-8 products. Testing for Safety: Are Impurities a Problem? Testing for Safety: Are Impurities a Problem? Table of Contents. Executive Summary.

THC 96

THC CBD Legalization Vaping 96

Puff Puff Post

NOVEMBER 5, 2019

INM-755 is a single-cannabinoid topical cream under development for the treatment of symptoms associated with epidermolysis bullosa (“EB”). INM-755 cream is a proprietary, topical, single-cannabinoid product candidate intended as a therapy in epidermolysis bullosa (EB) and potentially other dermatological applications.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

AUGUST 4, 2021

We thus provide comparison with the pre-pandemic period of H1 2019 as an additional data point. The Environment Testing business in North America was impacted by restrictions around sample collection and adverse weather conditions. On 22 April 2021, Mr. Pascal Rakovsky was appointed as Lead Independent Director.

Business 105

Business Research and Development Environment Food 105

Cannabis Law Report

JUNE 25, 2021

According to the federal government, the Cannabis Act’s three stated objectives are to (i) keep cannabis out of the hands of young people, (ii) keep profits out of the pockets of criminals, and (iii) protect public health and safety by allowing adults to access legal cannabis. Enforcement.

Cannabinoids 91

Cannabinoids Edibles Retail Cannabis 91

Cannabis Law Report

JUNE 4, 2021

Harris has written a variety of books that touch on the topics of consciousness, spirituality, and psychedelics. Through its discovery platform, Delix has identified a class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Hamilton Morris. in/jonathan-sporn-4ba7802/ [link].

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51